Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE Study

Jazieh, Abdul Rahman; Sağlam, Esra; Onal, Cem; Abdelkader, Y.; Gaafar, Rabab; Dawoud, Emad; Nassar, Mahmoud; Alshorbagy, D.; Ashry, H. El; Alsayed, MT

doi:10.1016/j.cllc.2022.02.002

Cited by 5 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, cCRT, CT alone, and sCRT were the most frequent treatment modalities in the MEA cohort and the global cohort (cCRT: 32% versus 29%, CT alone: 20% versus 17% and sCRT: 12% versus 10%). 7,20 Among resectable patients in the Egypt cohort, the majority (89.7%) underwent surgery-based therapy, in line with the recent NCCN and ESMO guidelines. 9,10 Among unresectable patients in Egypt, nearly half (48.8%) received CT alone, followed by 17.6% sCRT; only 9.3% received cCRT in first-line.…”

Section: Discussionmentioning

confidence: 57%

“…34 However, we found similar progression rates (73.9% versus 75.3%). The median PFS of the Egypt cohort was 10.3 months (95% CI, 9.43 12.02) – marginally lower than the MEA region (11.8 months) 20 and global cohorts (12.5 months). 7 However, the median OS for the Egypt subset was 18.5 months (95% CI, 16.46–21.88), substantially lower than the MEA region (22.9 months) 20 and the global cohort (34.9 months).…”

Section: Discussionmentioning

confidence: 78%

“…The KINDLE-Egypt subset represented a younger population with a median age of 59 years, as compared to the global KINDLE cohort (63 years) 7 and MEA KINDLE cohort (61 years). 20 The male predominance (male-to-female ratio of 3:1) in the Egyptian cohort could be attributed to high smoking rates among males. Approximately 41% of the patients in the Egyptian cohort were current smokers (current smokers in global cohort: 31.2%, MEA cohort: 37.7%), 7,20 and nearly one-fourth were ex-smokers.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Aboelhassan,

Sobeih,

El-Din

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We present findings on treatment patterns and their associated survival outcomes in patients with stage III NSCLC from the Egypt subset of the KINDLE global real-world study conducted across countries from Asia, Middle East, Africa, and Latin America. Method: Retrospective data from the Egypt subset (21 centers) of adult patients diagnosed with stage III NSCLC between January 2013 and December 2017 were analyzed. Descriptive and inferential statistics summarized treatment modalities, progression-free survival (PFS), and overall survival (OS). Results: Of 421 patients enrolled (median age: 59.0 years), 77.9% were males, 53.5% had stage IIIA disease, 60.8% had adenocarcinoma, 78.4% had an unresectable disease, and 81.5% had Eastern Cooperative Oncology Group performance status ⩽1. Overall, chemotherapy alone (40.4%) was predominantly used in the initial line, whereas definite radiotherapy was used in only 5.0% of patients. In resectable patients, chemotherapy plus surgery (33.8%), surgery alone (20.6%), or other surgery (20.6%) were the top three modalities used in initial line of treatment. Chemotherapy alone was most preferred (48.8%) in unresectable patients, followed by sequential chemoradiotherapy (CRT) (17.6%) and concurrent CRT (9.3%). The overall median PFS was 10.3 months [95% confidence interval (CI), 9.43–12.02], whereas the median OS was 18.5 months (95% CI, 16.46–21.88). Overall, female gender, adenocarcinoma histology, and radical therapy as surgery or CRT predicted significantly longer OS (all p < 0.05). Conclusion: KINDLE-Egypt cohort revealed wide heterogeneities in the treatment patterns of stage III NSCLC. Although deemed resectable, few patients did not undergo surgery, probably due to high smoking rates leading to poor lung function. Lower survival outcomes than other published real-world studies highlight the need for timely approval and availability of novel targeted and immunotherapies to enhance patient outcomes. Trial registration: NCT03725475

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Aboelhassan,

Sobeih,

El-Din

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…According to a similar study, 62.4% of the patients were male, and 37.6% were female 17 . Other studies in the Middle East and African countries also reported a male predominance of lung cancer cases 18 . The disease exhibits predominance in the male population compared with females.…”

Section: Discussionmentioning

confidence: 84%

“… 17 Other studies in the Middle East and African countries also reported a male predominance of lung cancer cases. 18 The disease exhibits predominance in the male population compared with females. This could be attributed to the history of smoking which accounts for more men smoking tobacco than women, increasing the incidence and mortality rates.…”

Section: Discussionmentioning

confidence: 99%

Assessment of survival outcomes among lung cancer patients at the National and Referral Hospital in Kenya

Said

Degu

2023

Cancer Medicine

View full text Add to dashboard Cite

Introduction Lung cancer has a low overall survival rate linked to late diagnosis and metastasis. Unfortunately, comprehensive data within the African continent are limited due to the lack of a registry, low public awareness of lung cancer, financial constraints, and inadequate screening and treatment facilities. In addition, there was a lack of conclusive data in our setting. Therefore, this study aimed to assess survival outcomes among lung cancer patients at Kenyatta National Hospital. Methods A hospital‐based retrospective cohort study was performed to examine the survival outcomes of 151 lung cancer patients. All eligible lung cancer patients diagnosed and treated in the facility between January 1, 2018, and December 31, 2020, were included. The patients were retrospectively followed from the date of primary cancer diagnosis until death or the last follow‐up period. The Statistical Package for the Social Sciences (SPSS) version 20.0 statistical software was used to enter and analyze the data. Kaplan–Meier survival and Cox regression analysis were employed to determine median survival and predictors of mortality, respectively. Results The mean and median follow‐time was 18.2 and 17.5 months, respectively. Most (98%) of the patients had non‐small cell lung cancer. The 2‐year survival rate was 66.7%, with 59.6% of patients having developed distant metastasis during the follow‐up, while 25.1% were deceased. The median cancer‐specific survival time among the study population was 18.0 ± 3.40 months. Cox regression analyses showed that patients with distant metastasis had five times more risk of dying (AHR: 4.74, 95% CI: 2.1–10.8, p < 0.001) than patients without distant metastasis. Conclusions The overall two‐year survival rate of lung cancer patients at the Kenyatta National Hospital was 66.7%, with most patients developed distant metastasis during the follow‐up period. Distant metastasis was the only significant predictor of mortality among lung cancer patients in our setting.

show abstract

Cancer research in the United Arab Emirates from birth to present: A bibliometric analysis

Al-Shamsi,

Abdelwahab,

Albasheer

et al. 2024

Heliyon

View full text Add to dashboard Cite

Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE Study

Cited by 5 publications

References 28 publications

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Assessment of survival outcomes among lung cancer patients at the National and Referral Hospital in Kenya

Cancer research in the United Arab Emirates from birth to present: A bibliometric analysis

Contact Info

Product

Resources

About